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Prox-1 Promotes Invasion of Kaposiform
Hemangioendotheliomas
Soheil S. Dadras1,2, Adrienne Skrzypek1, Lynh Nguyen1, Jay W. Shin1,3, Martin M.P. Schulz3, Jack Arbiser4,
Martin C. Mihm2 and Michael Detmar1,3
Kaposi’s sarcoma (KS) is the most frequently occurring malignant tumor in patients infected with HIV. Recent
studies have revealed that infection of vascular endothelial cells with KS-associated herpes virus in vitro results
in a lymphatic reprogramming of these cells, with potent induction of the lymphatic marker genes podoplanin
and vascular endothelial growth factor receptor-3, which is mediated by upregulation of the transcription factor
Prox1. However, the potential effects of Prox1 expression on the biology of KS and, in particular, on the
aggressive and invasive behavior of KS tumors in vivo have remained unknown. We stably expressed Prox1
cDNA in the two mouse hemangioendothelioma cell lines EOMA and Py-4-1, well-established murine models
for kaposiform hemangioendothelioma. Surprisingly, we found that expression of Prox1 was sufficient to
induce a more aggressive behavior of tumors growing in syngenic mice, leading to enhanced local invasion into
the muscular layer and to cellular anaplasia in vivo, and increased migration rate in vitro. This enhanced
malignant phenotype was associated with upregulation of several genes involved in proteolysis, cell adhesion,
and migration. Together, these results indicate that Prox1 plays an important, previously unanticipated role in
mediating the aggressive behavior of vascular neoplasms such as KS.
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INTRODUCTION
Kaposi’s sarcoma (KS) is the most frequently occurring
malignant tumor in patients infected with HIV (Su et al.,
1990), but also occurs in HIV-negative immunosuppressed
patients. KS mainly affects the skin and forms lesions of various
types, including early inflammatory and patch stage lesions, as
well as tumors with a predominant population of spindle cells.
Infection with Kaposi’s sarcoma-associated herpesvirus (KSHV)
is essential for KS tumor formation (Chang et al., 1994). In KS
lesions, KSHV-infected cells characteristically appear spindle
shaped and are associated with slit-like vessels/spaces that
often contain red blood cells. KS has been considered to be a
neoplasm of KSHV-infected lymphatic endothelium, due to the
morphological characteristics of the tumor cells and the
expression of several lymphatic lineage-specific genes includ-
ing vascular endothelial growth factor receptor-3 and podo-
planin by KS tumor cells. However, recent studies have
revealed that infection of vascular endothelial cells with KSHV
in vitro results in a lymphatic reprogramming of these cells,
with potent induction of the lymphatic marker genes
podoplanin and vascular endothelial growth factor receptor-
3 (Hong et al., 2004; Wang et al., 2004). Importantly, we
found that the transcription factor Prox1 is induced by
infection of vascular endothelium with KSHV, and that
knockdown of Prox1 interfered with the KSHV-mediated
induction of a lymphatic phenotype (Hong et al., 2004).
However, the potential effects of Prox1 expression on the
biology of KS and, in particular, on the aggressive and invasive
behavior of KS tumors in vivo have remained unknown.
The homeobox gene Prox1 is a transcription factor related
to the Drosophila gene prospero, which plays a major role in
the development of the central nervous system (Lavado and
Oliver, 2007), liver, and pancreas (Sosa-Pineda et al., 2000;
Burke and Oliver, 2002) and in lens fiber elongation (Wigle
et al., 1999). Importantly, Prox1 is a master gene controlling
the normal embryonic development and differentiation of the
lymphatic vasculature. Prox1-deficient mice are devoid of
lymphatic vasculature, and in these animals, endothelial cells
fail to acquire the lymphatic phenotype; instead, they remain
as blood vascular endothelium (Wigle and Oliver, 1999). We
and others have shown that ectopic expression of Prox1 in
differentiated blood vascular endothelial cells leads to
lymphatic endothelial reprogramming of these cells, asso-
ciated with downregulation of blood vascular-specific genes
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and upregulation of a number of lymphatic-specific genes
such as vascular endothelial growth factor receptor-3 and
podoplanin (Hong et al., 2002; Petrova et al., 2002).
Although the role of Prox1 in embryonic organogenesis
and lymphatic vasculogenesis is well established, its activity
in tumorigenesis remains poorly understood. Recently, Prox1
loss of function has been detected in diffuse large B-cell
lymphomas (Nagai et al., 2003), adenocarcinomas of the
biliary tract (Laerm et al., 2007), and hepatocellular
carcinomas (Shimoda et al., 2006), suggesting a possible
role of Prox1 as a tumor suppressor gene. In these types of
cancers, Prox1 loss of function was mainly due to genomic
deletions and epigenetic silencing. In contrast, Prox1 is
strongly expressed by human KSs in situ. Owing to the lack of
suitable mouse models of KS, however, the biological role of
Prox1 in KS pathology has been difficult to assess.
In this study, we used two established mouse models
of Prox1-negative kaposiform hemangioendotheliomas,
hemangioendothelioma (EOMA) cells (Hoak et al., 1971),
and Py-4-1 cells (Dubois-Stringfellow et al., 1994), to investi-
gate the biological effects of stable Prox1 expression on
tumor growth and invasion. Although nodular KS in children
can histologically mimic kaposiform hemangioendothelioma
the latter is a distinct entity and vascular tumor predomi-
nantly occurring in the retroperitoneum or soft tissues of
infants and the skin of young adults (Zukerberg et al., 1993),
associated with thrombocytopenia and hemorrhage (Sarkar
et al., 1997; Enjolras et al., 2000). Surprisingly, we found that
the expression of Prox1 was sufficient to induce a more
aggressive behavior of tumors growing in syngenic mice,
leading to enhanced local invasion into the muscular layer
and cellular anaplasia in vivo, and increased migration
in vitro. This enhanced malignant phenotype was associated
with upregulation of several genes involved in proteolysis,
cell adhesion, and migration. Our results indicate that Prox1
plays an important, previously unanticipated role in mediat-
ing the aggressive behavior of vascular neoplasms such as KS.
RESULTS
Stable overexpression of Prox1 in hemangioendothelioma
cell lines
We first investigated the expression of Prox1 in the parental
EOMA and Py-4-1 mouse hemangioendothelioma cell lines
by quantitative real-time reverse transcription-PCR (QRT-
PCR) and western blotting. We found that neither EOMA nor
Py-4-1 cells expressed endogenous murine Prox1 at the
mRNA (data not shown) or protein level (Figure 1a). Next, we
stably expressed a human Prox1 expression vector (pcDNA/
Prox1) or the empty vector alone (pcDNA) in both cell lines.
Human Prox1 shares more than 98% homology with the
murine protein at the amino-acid level. We isolated more
than 50 Prox1-expressing cell clones and compared
their human Prox1 mRNA levels to the endogenous murine
Prox1 expression levels of primary human lymphatic
endothelial cells, which are known to express high Prox1
levels (Hirakawa et al., 2003). EOMA and Py-4-1 stable
clones expressed human Prox1 mRNA in a wide range (data
not shown). Western blot analysis of cell lysates confirmed
efficient Prox1 protein expression in stable Py-4-1 Prox1
transfectants but not in the control clones (Figure 1a).
Differential immunofluorescence stains for Prox1 and for
the pan-endothelial marker CD31 confirmed strong nuclear
expression of Prox1 protein (Figure 1c), compared with a
weak background signal in the control clones (Figure 1b).
Human Prox1 protein expression was also confirmed in the
stable EOMA Prox1 clones (data not shown). Three indepen-
dent clones of control and Prox1-transfected EOMA and
Py-4-1 cells were selected for further studies.
In vivo growth and morphology of Prox1-expressing
hemangioendotheliomas
We first investigated the effect of different numbers of
implanted cells and the effect of added Matrigel matrix on
the growth and morphological characteristics of parental
EOMA and Py-4-1 tumors. We found that injection of 5105
EOMA or Py4-1 cells per site gave rise to tumors of
700–800mm3 in volume after 16 days. Injection of higher
cell numbers, that is, 1 106 or 2106, resulted in a lethality
of up to 43%, due to tumor burden, hemorrhage, and platelet
coagulopathy, similar to a previous study (Dubois-String-
fellow et al., 1994). Without the addition of Matrigel matrix
to the cell suspension, large cystic tumors formed but
frequently collapsed (Figure S1a). Admixture of cell clones
with Matrigel resulted in a rather regular, soft tumor mass
(Figure S1b). Addition of Matrigel accelerated the tumor
growth rate during the initial 4 days; however, this difference
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Figure 1. Overexpression of human Prox1 in stably transfected mouse
Py-4-1 cell clones. (a) Western blot analysis confirmed high amounts of Prox1
protein (80 kDa) in cell lysates obtained from Py-4-1 cells stably transfected
with pcDNA3-Prox1 vector (PP12, PP16, and PP21), as compared with
control transfectants (PC1-3). (b) Differential immunofluorescence stains for
Prox1 (green) and CD31 (red) demonstrated very weak background nuclear
signal for Prox1 and strong staining for the panvascular marker CD31 in a
control Py-4-1cell clone. (c) In contrast, a Py-4-1-Prox1 stable clone showed
strong Prox1 protein expression in the nucleus. Bar¼ 50 mm.
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normalized after 8 days (Figure S1c) when the average tumor
volume was similar in the presence (490.6mm3) or absence
(416mm3) of Matrigel. Lectin perfusion studies revealed that
the luminal surfaces of intra- and peritumoral vessels were
stained by fluorescent Lycopersicon esculentum (Figure
S1d–f), confirming efficient tumor perfusion. The tumors
usually formed an intradermal nodule with solid and cystic
architecture without well-formed vascular lumina, which
extended deep into the subcutis (Figure S1e). Tumor-
associated arteries and veins, stained by green fluorescent
lectin, were present deep within the subcutis (Figure S1f). No
significant necrosis was identified by routine histology.
We then injected three control (empty vector-expressing)
clones and three stably Prox1-expressing EOMA and Py-4-1
clones intradermally into the back skin of 129P3 and B6D2F1
mice, respectively. Analysis of total RNA extracted from
stable cell clones in vitro and from tumors, after 16 days of
in vivo growth, by QRT-PCR for Prox1 revealed that all
tumors maintained high levels of human Prox1 mRNA
expression (Figure 2a). The expression level of human Prox1
mRNA was comparable in the mouse cell clones and mouse
tumors with that of cultured human lymphatic endothelial
cells. Differential immunofluorescence analysis revealed
CD31-positive, intradermal tumor with solid and cystic
architecture without well-formed vascular lumina, in both
the control and Prox1-expressing tumors (data not shown),
whereas Prox1 showed a strong nuclear signal only in the
Prox1-transfected tumors (Figure 2c)—confirming stable and
robust exogenous Prox1 expression—but not in the control
tumors (Figure 2b).
Prox1 induces local invasion, anaplasia, and migration
of tumor cells
Histological analysis of tumor sections revealed two distinct
and reproducible morphologic alterations: (i) invasion of the
skeletal muscle by Prox1-expressing hemangioendothelioma
cells and (ii) severe cytologic atypia (anaplasia) of the Prox1-
expressing tumor cells, independent of cell line (both EOMA
and Py-4-1). Infiltration and destruction of the adjacent
skeletal muscle layer was seen in 45.5% of Prox1-expressing
tumors (10 of 22), usually located at the deep tumor margin,
but only in 6.3% of the control tumors (1 of 16, P¼0.004)
(Figure 3a–c). Given the local invasive behavior of Prox1
tumors in vivo, we examined the rate of migration in vitro
(Figure 3d). Monolayer wounding assays demonstrated a
significant increase in migration rates for three independent
Prox1-expressing Py-4-1 cell clones (PP8, PP11, PP17,
P¼0.0185) as compared with clones transfected only with
control vector (PC1, PC2, PC12). Despite the local invasive
behavior and increased migration, necropsy of all tumor-
bearing mice did not reveal any evidence of macroscopic or
microscopic metastases in the liver, lung, spleen, or lymph
nodes.
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Figure 2. Prox1 cell clones and their respective mouse tumor implants
maintained high levels of Prox1 expression. (a) QRT-PCR of total RNA
extracted from stable Prox1 clones (open bar) and from tumors (closed bar)
confirmed high levels of Prox1 mRNA expression, compared with primary
human lymphatic endothelial cells. All measurements are shown relative to
the expression levels of the human GAPDH housekeeping gene. Data shown
are the mean of RNA isolations from independent cell clones (n¼6) and
tumors (n¼ 6), all tested in triplicates±SEM. (b and c) Immunofluorescence
stains for Prox1 (green) and CD31 (red) demonstrated a strong nuclear signal
for Prox1 in Prox1-expressing tumor cells, but not in control tumor cells, and
in endothelial cells lining adjacent dermal lymphatic vessels (arrowheads).
Bar¼50 mm.
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Figure 3. Prox1 expression induced tumor cell invasion in vivo and
enhanced migration in vitro. (a and b) Histology of control and
Prox1-expressing tumor implants showed invasion of Prox1 tumors.
Prox1-expressing tumor cells (arrows) but not control tumors infiltrated the
skeletal muscle layer. Bar¼ 50mm. (c) The frequency of skeletal muscle
invasion was significantly increased in the Prox1-expressing tumors (n¼ 22,
P¼ 0.004) in comparison with controls (n¼ 16). (d) Monolayer wounding
in vitro assay showed significantly increased migration rates for
Prox1-expressing Py-4-1 cell clones (PP8, PP11, PP17, P¼ 0.0185) as
compared with clones transfected with only control vector (PC1, PC2, PC12).
Data are shown as mean±SEM. Each bar represents the result of three
independent experiments.
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When examined under low-power magnification, both
control and Prox1 tumors showed similar histological
findings: solid and cystic architecture without well-formed
vascular lumina, composed of sheets of tumor cells, pools of
erythrocytes, and remnants of Matrigel matrix (Figure S2a–b).
Surprisingly, when examined under high-power magnifica-
tion, we frequently identified severe cytologic atypia
(anaplasia), as evidenced by nuclear pleomorphism and
hyperchromasia, in the Prox1 tumors (59.1%, 13 of 22)
(Figure S2d), but only rarely in the control tumors (11.8%, 2
of 17; P¼ 0.001) (Figure S2c). An enhanced mitotic activity
was not identified during routine histological examination.
These findings, together with the previously suggested
potential role of Prox1 in cell proliferation during eye
development (Wigle et al., 1999), prompted us to measure
the cellular proliferation rate of Prox1-expressing cell clones.
However, we detected no change in the growth rate of Prox1
cell clones in vitro, as compared with the control clones
(Figure S2e). Similarly, Prox1 tumors did not exhibit an
accelerated growth rate compared with the control tumors
(Figure S2f), and no significant change in the average weight
was detected between Prox1 tumors (0.33±0.23 g, n¼32)
and control tumors (0.40±0.18 g, n¼16; P¼0.14). Similar
results were obtained for Prox1-expressing EOMA cells (data
not shown). Overall, these results show that Prox1 expression
leads to enhanced cellular invasion, nuclear pleomorphism,
and migration without enhancing the cellular proliferation
rate.
Differential immunofluorescence analysis of CD31 and
LYVE-1 expression demonstrated numerous peritumoral
blood vessels, but only a few peritumoral lymphatic vessels
(Figure 4a–b). Computer-assisted morphometric analysis, in
both the control and Prox1 tumor sections, revealed no
significant difference in the peritumoral blood vessel density,
size, or relative blood vascular area in the Prox1 tumors
(n¼18), compared with the control tumors (n¼19)
(Figure 4c). Similarly, no significant changes were detected
in the peritumoral lymphatic vessel density, size, or relative
lymphatic vascular area (data not shown).
Prox1 induces genes involved in proteolysis and lymphatic
differentiation
The enhanced invasiveness of Prox1-expressing hemangioen-
dotheliomas prompted us to investigate the underlying
molecular mechanisms. Comparative gene array analyses of
cultured control and Prox1 clones revealed that stable
overexpression of Prox1-induced genes that are involved in
proteolysis, cell adhesion, migration, differentiation, regula-
tion of gene transcription, and fatty acid metabolism (Table 1).
Two of the most potently induced genes were von Willebrand
factor and alpha fetoprotein (AFP; Table S1). Prox1 also
regulated several hyaluronan-related genes, including the
lymphatic-specific hyaluronan receptor LYVE-1, which ap-
pears as extracellular link domain-containing 1 (Xlkd1) (Table
S1). We next used QRT-PCR of total RNA extracted from
cultured cells and from tumors to validate select genes that
were most potently regulated by Prox1 based on the gene-
array results (Table 2). We found that the expressions of von
Willebrand factor, alpha fetoprotein, and LYVE-1 were
strongly upregulated in cultured Prox1-expressing clones
PP8, PP11, and PP12, as well as in their respective tumors.
Although Prox1 did not upregulate the expression of the
lymphatic marker podoplanin in cultured cells, podoplanin
was significantly upregulated in the Prox1 tumors (Table 2).
Then, we performed immunofluorescence analyses of
selected Prox1-induced targets in paraffin-embedded tumor
sections. We found a strong increase in LYVE-1 protein
expression in the cytoplasm and cell membrane of Prox1-
expressing tumors compared with control tumors (Figure
S3a–b and Figure 4b). In particular, LYVE-1-positive tumor
cells were found to infiltrate the skeletal muscle layer (Figure
S3c). Immunohistochemical analysis of von Willebrand
factor, AFP, and podoplanin confirmed focal expression in
the cytoplasm of Prox1 tumor cells but not in the control
tumors (data not shown).
DISCUSSION
Our results reveal that stable (chronic) overexpression of the
transcription factor Prox1 in mouse hemangioendothelioma
cells induces an invasive phenotype in vivo and enhanced
migration rate in vitro, promotes expression of genes involved
in cell migration and proteolysis, and also partially repro-
grams these cells to acquire the expression of lymphatic
endothelium-specific genes. Previous studies have revealed
that Prox1 is a master gene controlling the embryonic
development of the lymphatic vascular system in mice (Hong
et al., 2002). Moreover, Prox1 is also involved in cell
fate decisions in other organ systems, such as the central
nervous system (Lavado and Oliver, 2007), liver, and
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Figure 4. Prox1 expression did not induce tumor angiogenesis or
lymphangiogenesis. (a and b) Immunofluorescence stains for LYVE-1 (green)
and CD31 (red) revealed a few dermal lymphatics (arrowheads) and
numerous tumor-associated blood vessels. Note: Prox1 tumor cells
demonstrated significantly enhanced LYVE-1 expression localized to the
cytoplasm and membrane. Bar¼ 50mm. (c) No change of tumor-associated
blood vascular density, size, or relative area was detected in the Prox1 tumors
(n¼18), compared with the control (n¼19). Data are shown as mean±SEM.
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pancreas (Sosa-Pineda et al., 2000; Burke and Oliver, 2002),
and in lens fiber elongation (Wigle et al., 1999). Importantly,
recent studies have shown that transient (short-term) over-
expression of Prox1 in vascular endothelial cells promotes
expression of a number of lymphatic-specific genes while
downregulating several blood vascular genes (Hong et al.,
2002; Petrova et al., 2002), and that Prox1 is involved in the
lymphatic reprogramming of vascular endothelium by the
KS-associated herpes virus (Hong et al., 2004). Moreover,
Prox1 expression has been found in some types of tumors
where its role has remained unclear (Nagai et al., 2003;
Shimoda et al., 2006; Laerm et al., 2007). However, the
biological effects of stable overexpression of Prox1 have
remained unknown.
Our study reveals that stable overexpression of Prox1 does
not promote in vitro proliferation of tumor cells or in vivo
tumor growth. Instead, Prox1 expression leads to a more
aggressive tumor phenotype of vascular tumors, as evidenced
by increased local invasion into the muscle layer and by
cellular anaplasia. This local invasive behavior is corrobo-
rated by the enhanced migration rate of Prox1-expressing
Py-4-1 cells in vitro. These results are in agreement with
Table 1. Selected genes upregulated in Prox1-expressing cells according to biological processes
Fold change (sorted by mean)
Prox1/control microarray Prox1/control microarray
Symbol Name I II
Proteolysis
Prss23 Protease, serine, 23 2.537 25.233
Serpina3g Serine (or cysteine) peptidase inhibitor, clade A member 3G 5.864 7.317
Casp12 Caspase 12 2.077 6.862
Usp45 Ubiquitin-specific peptidase 45 2.555 3.605
Tll1 Tolloid-like 3.080 1.698
Wwp1 WW domain-containing E3 ubiquitin protein ligase 1 2.599 1.820
Lipid, fatty acid, and steroid metabolism
Sc4mol Sterol-C4-methyl oxidase-like 3.355 12.441
Cyp1b1 Cytochrome P450, family 1, subfamily b, polypeptide 1 2.497 4.616
Plscr2 Phospholipid scramblase 2 2.998 3.164
Fabp4 Fatty acid-binding protein 4, adipocyte 1.781 3.896
Pik3c2a Phosphatidylinositol 3-kinase, C2 domain-containing, alpha 2.023 3.262
Fdft1 Farnesyl diphosphate farnesyl transferase 1 2.696 2.296
Ltc4s Leukotriene C4 synthase 1.968 2.634
Pparg Peroxisome proliferator activated receptor gamma 2.042 2.258
Impad1 Inositol monophosphatase domain containing 1 2.444 1.808
Cell adhesion
Vwf Von Willebrand factor homolog 38.429 23.760
Cdh1 Cadherin 1 19.111 2.069
Selp Selectin, platelet 3.901 7.798
Nid2 Nidogen 2 4.491 3.358
Hspg2 Perlecan (heparan sulfate proteoglycan 2) 2.109 4.806
Ctnnal1 Catenin (cadherin associated protein), alpha-like 1 4.253 2.659
Col8a1 Procollagen, type VIII, alpha 1 1.762 4.932
Pkp2 Plakophilin 2 1.630 2.824
Cell structure and motility
Gem GTP-binding protein 3.795 4.693
Ctnnal1 Catenin (cadherin-associated protein), alpha-like 1 4.253 2.659
Foxp1 Forkhead box P1 1.815 4.894
Fblim1 Filamin-binding LIM protein 1 2.208 2.445
Klhl7 Kelch-like 7 (Drosophila) 2.717 1.915
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findings in Prox1-deficient mice, where the migration of
lymphatic precursor cells away from the cardinal vein is
strongly inhibited (Wigle and Oliver, 1999). It remains to
be investigated whether Prox1 expression is upregulated in
wound-associated lymphatic endothelial cells and might
thereby also contribute to lymphatic vessel migration into
the granulation tissue. Gene array profiling studies revealed
that the invasive tumor phenotype is associated with
upregulation of genes involved in proteolysis, cell adhesion,
and migration. For example, Prox1 induced the expression of
genes encoding tissue proteases, including serine protease
23. Thus, Prox1 likely enhances cellular invasion by
promoting proteolysis of extracellular matrix proteins and
enhancing cellular motility and migration. The observed
cellular anaplasia in Prox1 tumors may be related to the
upregulated expression of genes controlling cell differentia-
tion, such as AFP. AFP is normally synthesized in the liver,
the intestinal tract, and the yolk sac of the fetus; however, this
fetal protein is reexpressed in hepatocellular carcinomas and
in some adult tumors that exhibit an embryonic state of
differentiation, such as germ cell neoplasms and yolk sac
tumors.
Prox1 overexpression did not significantly accelerate the
proliferation rate of EOMA and Py-4-1 cells in vitro or in vivo.
These findings are supported by our gene array analysis,
which did not detect major stimulation of the expression of
genes linked to cell cycle progression, such as cyclins A2, B2,
D3, E1, H, histone H3, histone H4, or proliferating cell
nuclear antigen. However, the observed downregulation of
Cdkn1b in Prox1-expressing clones is in agreement with
recent findings during embryonic lens fiber development in
Prox1-null mice where downregulated expression of the cell
cycle inhibitors Cdkn1b and Cdkn1c was reported (Wigle
et al., 1999). These differences may be explained by cell
type- and differentiation state-specific differences of the
Prox1 response.
Importantly, the chronic expression of Prox1 in Prox1-
negative hemangioendothelioma cells resulted in the acquisi-
tion of a partial lymphatic phenotype by these cells, in
agreement with recent studies with transient Prox1 expression
in normal human vascular endothelial cells (Hong et al.,
2002; Petrova et al., 2002). The chronic versus transient Prox1
expression has generated distinct biological consequences of
gene expression pattern exhibiting some interesting differ-
ences. First, we did not detect a significant upregulation of
podoplanin in vitro; however, its strong expression in Prox1
tumor cells in situ was evident. Although the mechanism of
this finding is unknown at this point, a recent study has
indicated some intrinsic in vitro versus in vivo differences
in the regulation of lymphatic lineage-specific genes
(Amatschek et al., 2007), likely controlled by microenviron-
mental cues. Second, LYVE-1 expression is upregulated both
in vitro and in vivo. Although our data does not provide
mechanistic explanation for this finding, LYVE-1 is upregu-
lated at both mRNA and protein levels in Prox1-expressing
cell lines and tumors, which is also corroborated by our gene
array analysis. The observed cytoplasmic LYVE-1 staining in
Prox1-expressing tumor cells, which can also be found on
lymphatic endothelium, indicates that LYVE-1 might be
expressed on intracytoplasmic structures, in addition to its
well-established localization at the membrane level.
Although kaposiform hemangioendothelioma (O’Reilly
et al., 1997) and KSs are two distinct clinicopathological
entities, we demonstrate that mouse hemangioendothelioma
cells expressing chronic and ectopic human Prox1 exhibit
genotypic and phenotypic features resembling human KS.
These characteristics include expression of Prox1, other
lymphatic markers (such as LYVE-1 and podoplanin), lack
of well-formed vascular lumina, a connection to the systemic
circulation, and local invasive behavior. Erythrocyte-filled
vascular spaces and detection of fluorescently labeled lectin,
after intravenous injection, provide direct morphological
evidence that Prox1-expressing tumors are efficiently per-
fused because they are connected to the systemic circulation.
This is in contrast to lymphangioma circumscriptum, a
lymphatic vascular lesion, disconnected from the blood
vascular system, as evidenced by the absence of erythrocytes
in vascular spaces (Flanagan and Helwig, 1977). It is
important to note that infantile hemangiomas—that are
usually noninvasive and that do not show signs of cellular
anaplasia—express several lymphatic markers but not Prox1
(Dadras et al., 2004), whereas KSs that upregulate Prox1 via a
KSHV-mediated mechanism (Hong et al., 2004) display
invasive properties. Thus, it is tempting to speculate that the
upregulation of Prox1 contributes to the malignant behavior
of KSs.
Table 2. Quantitative real-time RT-PCR analysis of Prox1-induced genes in Prox1 clones and respective tumors
Gene Control clone Prox1 clone P-value Control tumor Prox1 tumor P-value
von Willebrand factor ND 4.4±0.60 o0.0001 0.96±0.17 4.1±0.43 o0.0001
AFP ND 3.3±0.07 o0.0001 0.26±0.16 1.5±0.07 0.0046
LYVE-1 0.28±0.12 4.4±0.59 o0.0001 0.97±0.17 4.3±0.50 o0.0001
Podoplanin ND 0.38±0.27 0.2302 1.98±0.57 8.57±1.47 0.0028
Flt-4 0.29±0.12 1.8±0.25 0.0001 0.43±0.12 0.49±0.14 0.8102
Data are derived from three individual clones for control and Prox1 constructs and their respective tumors in triplicate. All measurements (fold-induction) are
shown relative to the expression levels of mouse GADPH housekeeping gene. ND, not detected.
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Unexpectedly, Prox1 overexpression resulted in the
upregulation of several genes involved in fatty acid metabo-
lism, such as very low density lipoprotein receptor, fatty acid
binding protein 4, and peroxisome proliferator activated
receptor gamma, among others (Table 1; Table S1). Lympha-
tic vessels in the intestine—that strongly express Prox1—play
a major role in the uptake of fatty acids and of the lipid-
soluble vitamins A, D, E, and K (Cueni and Detmar, 2006).
Recent studies in Prox1-deficient mice have shown that
heterozygous Prox1-deficient mice are characterized by
extreme obesity specifically caused by reduced Prox1
expression in lymphatic endothelium (Harvey et al., 2005).
Moreover, there has been a long-known association of
lymphatic dysfunction with fat accumulation in tissues (Witte
et al., 1997). Thus, our study also provides novel insights into
the potential mechanisms by which Prox1 might modulate
lipid metabolism and that might link lymphatic dysfunction
and obesity.
In conclusion, our data show that Prox1 gain of function
results in a more aggressive vascular tumor phenotype
with partial lymphatic differentiation, representing key
features of KS. To our knowledge, this is previously
unreported. Further studies are needed to evaluate the
potential biological role of Prox1 in different types of
nonvascular malignant tumors.
MATERIALS AND METHODS
Cell transfection and selection
The mouse hemangioendothelioma cell lines EOMA (Obeso et al.,
1990) and Py-4-1 (Dubois-Stringfellow et al., 1994) were maintained
in complete DMEM (high glucose) with 20% fetal bovine serum,
4mM L-glutamine, and 1% antibiotic–antimycotic solution (Invitro-
gen, Carlsbad, CA). EOMA and Py-4-1 cells were transfected with a
pcDNA vector alone or with a pcDNA/Prox1 expression vector,
containing the full-length human Prox1 cDNA and a neomycin-
resistance cassette (kindly provided by Dr S.I. Tomarev, National Eye
Institute, Bethesda, MD), using the Superfect transfection reagent
(Qiagen, Chatsworth, CA). Transfected cells were selected in
medium containing 0.4mgml1 (for EOMA) and 0.8mgml1 (for
Py-4-1) G418 (Invitrogen). Stably transfected cell clones were
individually expanded and analyzed for Prox1 mRNA and protein
expression (Hong et al., 2002).
Gene array analyses
Total cellular RNA was extracted from two stably Prox1-expressing
Py-4-1 cell clones and two control-transfected Py-4-1 cell clones.
Microarray analyses were performed using the mouse 430A 2.0
Array GeneChip (Affymetrix, Santa Clara, CA; containing B22,690
genes) according to the manufacturer’s instructions. Arrays were
scanned using an Affymetrix confocal scanner and analyzed by the
Microarray Suite 5.0 software (Affymetrix) as described (Hong et al.,
2004) (Geo accession number GSE8171). Intensity values were
scaled so that the overall fluorescence intensity of each chip of the
same type was equivalent. Genes with a fold change of 1.7 or greater
in both array comparisons (Prox1-expressing clones versus control-
transfected clones) were considered as increased or decreased.
Panther software (http://www.pantherdb.org/) was used to assign
biological processes to significantly overrepresented genes in
Prox1-expressing cells, as compared with control-transfected cells
(Table S1).
RNA isolation and QRT-PCR analysis
Total cellular RNA was isolated from cultured cells and from tumors
using the TRIzol method (Invitrogen) as described (Streit et al., 1999).
After treatment with RQ1 RNAse-free DNase (Promega, Madison,
WI), dual-labeled probe-based real-time RT-PCR reactions were
performed as described (Hong et al., 2004), using an ABI Prism 7000
Sequence Detection System and TaqMan EZ RT-PCR Core Reagent
(Applied Biosystems, Foster City, CA). The gene-specific probes were
labeled with 6-FAM and TAMRA, and then multiplexed with
GAPDH primers, labeled with JOE and TAMRA, as an internal
control (Table S2), as described (Hong et al., 2002). For each sample,
0.2 mg of total RNA were used and all reactions were performed in
triplicates.
Western blot analyses
Cells grown to 80% confluency in 10-cm plates were scraped in
lysis buffer (50mmol l1 HEPES, 150mmol l1 NaCl, 1% Triton
X-100, 30mmol l1 Na-pyrophosphate, 50mmol l1 Na-fluoride,
1mmol l1 Na-orthovanadate, pH 7.4) containing protease inhibi-
tors (0.02mol l1 phenylmethylsulfonyl fluoride, 50 mgml1 leupep-
tin, and 50 mgml1 aprotinin) (Sigma, St Louis, MO). The cell lysates
were collected and centrifuged at 14,000 r.p.m. for 10minutes. After
measuring the protein concentration using the BCA protein assay
(Pierce, Rockford, IL), the supernatants were denatured in Laemmli
sample buffer (Bio-Rad, Hercules, CA) using b-mercaptoethanol at
95 1C for 5minutes, and 30 mg of the total protein was subjected to
SDS-PAGE in duplicates. One protein gel was stained with
Coomassie blue for loading control and the other blotted onto
nitrocellulose membranes (Bio-Rad, Hercules, CA). Membranes
were incubated in 5% nonfat milk–phosphate-buffered saline
blocking solution overnight and were incubated with rabbit
antiserum against human Prox1 (1:1,000) (Table S3). After washes,
membranes were incubated with horseradish-peroxidase-conjugated
anti-rabbit IgG (1:2,000, Amersham Biosciences, Piscataway, NJ)
and analyzed by the enhanced chemiluminescence system (Amer-
sham Biosciences).
Cell growth assays
Control and Prox1-expressing Py-4-1 clones were seeded into 96-
well plates (1,600 cells per well, n¼ 5 per clone; three independent
control and three Prox1 clones) and were incubated with or without
serum for 48 hours. The cells were then incubated in a 0.1mgml1
4-methylumbelliferyl heptanoate (Sigma)/phosphate-buffered saline
solution for 1 hour at 37 1C as described (Detmar et al., 1992). After
washing, the fluorescence intensity—that corresponds to the number
of viable cells (Detmar et al., 1992)—was measured using a Victor2
Fluorometer (PerkinElmer, Boston, MA). The assay was repeated
twice with comparable results.
In vitro monolayer wounding assay
Three independent control (PC1, PC2, PC12) and three independent
Prox1-expressing Py-4-1 clones (PP8, PP11, PP17) were seeded into
24-well plates at a density of 2 105 cells per well (n¼ 8 per clone).
After reaching confluence, cell monolayers were wounded with
a 200ml pipette tip, washed with phosphate-buffered saline
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(Gibco-Invitrogen, Paisley, UK), and incubated in serum-reduced
medium (2% fetal bovine serum) for 24 hours. Identical wounded
areas were imaged at time point 0 and 24hours with a phase-
contrast microscope, and the absolute open area (not covered by
cells) was quantified using Photoshop CS3 (Adobe, San Jose, CA).
The percentage of open area after 24 hours, as compared with
0 hours was determined with Excel 2003 (Microsoft, Redmond, WA).
The assay was performed thrice with comparable results.
Tumorigenesis assays and morphologic evaluation
The parental and the stably transfected EOMA and Py4-1 cells were
injected intradermally on each side of the back skin of 8-week-old
female 129P3 and B6D2F1 mice, respectively (Jackson Laboratory,
Bar Harbor, ME). To improve in vivo growth conditions, cells were
mixed with growth factor-reduced Matrigel Matrix (BD Biosciences,
San Jose, CA) at a 1:5 ratio. We injected a total of 14 independent
clones for the evaluation of tumorigenesis and morphology; each
independent cell clone was tested in at least 3–5 mice resulting in a
tally of at least 42 mice. Six control clones were selected from both
EOMA and Py4-1 cell lines, which were transfected with the empty
vector (pcDNA3); these six control clones (PC1, PC2, PC3, EC25,
EC27, and EC29) grew as control tumors. Eight Prox1-expressing cell
clones from both EOMA and Py4-1 cell lines (PP8, PP11, PP12,
PP16, PP21, EP38, EP44 and EP55), which were transfected with the
Prox-1 expression vector (pcDNA/hProx-1), grew as Prox1 tumors.
Necropsy and histological analysis were performed on all tumor-
bearing mice to detect possible organ or lymph node metastases. All
tumors were harvested 14 days after injection and were formalin-
fixed for histological analyses. Two pathologists (S.S.D. and M.C.M.)
analyzed tumor invasion and tumor cell differentiation, while
blinded to the identity of cell clones. The presence of tumor cells
in adjacent skeletal muscle defined tumor invasion, and tumor cell
differentiation was defined by the presence of at least five
pleomorphic cells with highly atypical nuclei per  10 field. All
animal studies were approved by the Massachusetts General
Hospital Subcommittee on Research Animal Care.
Vascular perfusions
Mice bearing EOMA- and Py-4-1-derived tumors were subjected to
lectin vascular perfusions as described previously (Thurston et al.,
1998). Briefly, anesthetized mice received 200 ml of 1mgml1 FITC-
conjugated L. esculentum lectin (Vector Laboratories, Burlingame,
CA) into the retro-orbital sinus. After 2minutes, the mice were
perfused with 60ml of a 1% paraformaldehyde solution and then
with 60ml phosphate-buffered saline for 60 seconds. After the
embedding of tumors and kidneys (positive control for perfusion) in
optimal cutting temperature compound (Miles, Elkhart, IN), 5 mm
cryostat sections were fixed in 4% paraformaldehyde at room
temperature for 20minutes and were stained with Hoechst
bisbenzimide.
Immunostaining and morphometric vessel analysis
Differential immunofluorescence analyses were performed on 5-mm
cryostat sections, using a rabbit polyclonal antibody against murine
LYVE-1 (kindly provided by Dr David Jackson) and a rat mAb against
murine CD31 (Table S3), followed by secondary antibodies, as
described previously (Dadras et al., 2003). Additional immunohisto-
chemical analyses were performed using antibodies against AFP,
von Willebrand factor, podoplanin, and Prox1 (Table S3). For
specificity controls, the primary antibodies were omitted. Cell nuclei
were counterstained with Hoechst bisbenzimide or hematoxylin.
Computer-assisted morphometric analyses of tumor-associated
lymphatic and blood vessel density and size were performed in a
total of 13 tumors (control, n¼ 6; and Prox1 expressing, n¼ 7), using
the IP-Lab software (Scanalytics, Fairfax, VA) as described previously
(Dadras et al., 2003). For each tumor section, three fields with the
highest lymphatic or blood vascular density (‘‘hot spots’’) were
evaluated at  100 magnification. Tumor borders were determined
on serial sections, using Hoechst bisbenzimide nuclear stains at
20 mgml1 and hematoxylin-and-eosin (H&E) stains.
Statistical analyses
The unpaired Student’s t-test was used to determine the statistical
significance (P-value) of the mean for all vascular parameters, real-
time RT-PCR, tumor cell differentiation, and invasion assays and
in vitro monolayer wounding assay.
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